The canine arthritis treatment types include non-steroidal anti-inflammatory medications (NSAIDs), opioids and stem cell Canine Arthritis Treatment. Non-steroidal anti-inflammatory Canine Arthritis Treatment are used to control pain and inflammation associated with arthritis. They are most commonly used canine arthritis treatment drugs. NSAIDs are used to treat mild to moderate pain by reducing the production of prostaglandins, which is involved with inflammation and discomfort. Several non-steroidal anti-inflammatory medications approved for canine arthritis treatment are Ketaprofen, Carprofen, Deracoxib, and Rimadyl, among others. Opioids are another class of pain relief medication for canine arthritis treatment, which includes Tramadol, Tapentadol, and buprenorphine, among others. Opioids work by acting through the central opioid receptors. They are used to treat moderate to severe as well as chronic pain associated with arthritis. The stem cell therapy is a new treatment option for canine arthritis treatment. The stem cell Canine Arthritis Treatment is usually performed as canine arthritis treatment using either autologous stem cells or allogeneic stem cells Canine Arthritis Treatment. In the stem cell canine arthritis treatment, the adult stem cells are harvested from canine’s fat tissues and injected into the affected joints. The stem cell Canine Arthritis Treatment has improved the quality of life of canines by reducing pain and increasing mobility and has shown 85% success rate within 5 months of canine arthritis treatment.
Scope of the Report:
This report studies the Canine Arthritis Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Canine Arthritis Treatment market by product type and applications/end industries.
The global Canine Arthritis Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Canine Arthritis Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Elanco (Eli Lilly and Company)
Boehringer Ingelheim
Zoetis Inc
Vetoquinol S.A.
Bayer AG
Aratana Therapeutics Inc
Norbrook Laboratories Limited
VetStem Biopharma
Dechra Pharmaceuticals Plc
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Non-Steroidal Anti-Inflammatory Drugs
Opioids
Stem Cell Therapy
Market Segment by Applications, can be divided into
Veterinary Hospitals and Clinics
Retail Pharmacies
Drug Stores
E-commerce
Summary:
Get latest Market Research Reports on Canine Arthritis Treatment . Industry analysis & Market Report on Canine Arthritis Treatment is a syndicated market report, published as Global Canine Arthritis Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Canine Arthritis Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.